AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Nanomosaic Closes A $40.75Mm Over-Subscribed Series A Round

Dec 06, 2021•over 3 years ago

Amount Raised

$40.8 Million

Round Type

series a

Boston

Description

NanoMosaic Inc., a Tiger Gene founded company that has established itself as the pioneer and leader in nanoneedle (MosaicNeedleTM) detection for proteomics and multi-omics applications, announced today that it has closed an oversubscribed $40,750,000 Series A round of financing led by RA Capital Management, joined by Insight Partners, Pura Vida Investments, Time BioVentures and Tiger Gene. Aiming to break the bottleneck in protein biomarker interrogation, NanoMosaic has developed a suite of analyte interrogation technologies and has successfully exported its platform to leading hospitals and institutes.

Company Information

Company

Nano Mosaic

Location

Boston, Massachusetts, United States

About

NanoMosaic, a Boston-based biotechnology company, is the only commercial entity to leverage the power of nanoneedles, MosaicNeedlesTM, for protein detection and quantification to develop best-in-class assays for biomarker discovery and validation. The NanoMosaic platform, TessieTM, alleviates the bottlenecks in proteomics analysis and provides an end-to-end solution that enables first of its kind protein interrogation and multi-omics analysis within a single chip on one run. The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content. The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics. www.nanomosaicllc.com CONTACT: Audrey Warner, audrey.warner@tigergenellc.com SOURCE NanoMosaic

Company News

(4 articles)

Wed, 12 Feb 2025 08:00:00 GMT

Nanomosaic Announced Release of Joint White Paper with BMS Investigating Nanoneedle Technology to Improve AAV Manufacturing Process and Product Quality - PR Newswire

Mon, 06 Dec 2021 08:00:00 GMT

NanoMosaic Closes a $40.75MM Over-Subscribed Series A Round - PR Newswire

Wed, 06 Mar 2024 08:00:00 GMT

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization - PR Newswire

Tue, 15 Feb 2022 08:00:00 GMT

NanoMosaic Announces Its Second Commercial Sale of the World's First Proteomics/Multi-Omics System, Tessie™, for Clinical Diagnostic Test Development, Under Its Early Access Program - PR Newswire

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech